Cytotoxic agents comprising maytansinoids and their therapeutic use
First Claim
1. A cytotoxic agent comprising one or more maytansinoids linked to a monoclonal antibody or fragment thereof via a disulfide bridge at the C-3, -14, -15, or -20 position of said maytansinoids and wherein said monoclonal antibody or fragment thereof is selective for tumor cell antigens.
1 Assignment
0 Petitions
Accused Products
Abstract
A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier diluent or excipient. A method for killing selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. An N-methyl-alanine-containing ester of maytansinol or an analogue of maytansinol, said N-methyl-alanine-containing ester comprising a linking group capable of linking an N-methyl-alanine-containing maytansinoid ester to a chemical moiety. N-methyl-cysteine-containing ester of maytansinol or an analogue of maytansinol.
-
Citations
18 Claims
- 1. A cytotoxic agent comprising one or more maytansinoids linked to a monoclonal antibody or fragment thereof via a disulfide bridge at the C-3, -14, -15, or -20 position of said maytansinoids and wherein said monoclonal antibody or fragment thereof is selective for tumor cell antigens.
-
7. A pharmaceutical composition comprising:
-
(a) one or more maytansinoids linked to a monoclonal antibody or fragment thereof via a disulfide bridge at the C-3, -14, -15 or -20 position of said maytansinoids and wherein said monoclonal antibody or fragment thereof is selective for tumor cell antigens, and (b) a pharmaceutically acceptable carrier, diluent or excipient. - View Dependent Claims (8, 9, 10, 11, 12)
-
- 13. A method for treating cancer sensitive to treatment with said method, said method comprising parenterally administering to a patient in need thereof an effective dose of a composition comprising one or more maytansinoids linked to a monoclonal antibody or fragment thereof via a disulfide bridge at the C-3, -14, -15 or -20 position of said maytansinoids and wherein said monoclonal antibody or fragment thereof is selective for tumor cell antigens.
Specification